1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pathology Analysis & Statistics 2022 - Europe

Pathology Analysis & Statistics 2022 - Europe

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Datamonitor Healthcare
1-30 of 98 reports

Chronic Heart Failure Pricing, Reimbursement, and Access

  • $ 7500
  • April 2018
  • 79 pages

Overview  Payers were originally extremely worried about the potential cost burden of Entresto, however, the level of concern surrounding the drug is currently moderate as physician uptake has been ...

  • United States
  • Europe
  • Cardiovascular Drug
  • Health Care Provider
  • Industry analysis

Crohn’s Disease and Ulcerative Colitis Pricing, Reimbursement, and Access

  • $ 7500
  • March 2018
  • 204 pages

Overview  Payers view spending on inflammatory bowel disease (IBD) drugs as significant, as there is a large patient base requiring expensive biologic therapies. The market has been long dominated ...

  • Europe
  • United States
  • Autoimmune Disease
  • Biopharmaceutical
  • Industry analysis

Crohn’s Disease: Treatment

  • $ 3739
  • December 2017
  • 52 pages

Description Datamonitor Healthcare surveyed 240 gastroenterologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain insight into Crohn’s disease diagnosis, ...

  • United States
  • Japan
  • Digestive System Disorder
  • Industry analysis
  • Biosimilar Penetration Rate

Crohn’s Disease: Pipeline

  • $ 3217
  • December 2017
  • 60 pages

Description In-depth analysis of pipeline products for Crohn’s disease in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including new clinical data and an evaluation ...

  • Spain
  • France
  • Digestive System Disorder
  • Industry analysis

Crohn’s Disease: Forecast

  • $ 4521
  • December 2017
  • 83 pages

Description Datamonitor Healthcare uses a patient-based approach to size the Crohn’s disease market opportunity across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the ...

  • United States
  • European Union
  • Digestive System Disorder
  • Industry analysis

Crohn’s Disease: Epidemiology

  • $ 3130
  • December 2017
  • 61 pages

Description This epidemiologic analysis uses robust, country-specific data sources to estimate and forecast diagnosed prevalent cases of Crohn’s disease (CD) in the US, Japan, and five major EU markets ...

  • Japan
  • United States
  • Healthcare
  • Digestive System Disorder
  • Industry analysis

Merck KGaA Company Analysis

  • $ 3000
  • December 2017
  • 28 pages

Updated analysis and forecasts based on Q3 2017 company-reported sales. PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed ...

  • Europe
  • United States
  • Prescription Drug
  • Cancer
  • Company research
  • Company

5EU Surgical Procedure Volumes: Cardiovascular and Peripheral Vascular Procedures

  • $ 3000
  • December 2017
  • 118 pages

This report presents procedure volumes forecasts for some of the most common cardiovascular and peripheral vascular surgical procedures performed in the five EU countries of France, Germany, Italy, Spain, ...

  • Spain
  • France
  • Hospital
  • Cardiology
  • Industry analysis
  • Surgical Procedures Performed

Company Analysis: AbbVie

  • $ 3000
  • November 2017
  • 40 pages

Updated analysis and forecasts based on Q3 2017 company-reported sales. PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed ...

  • Europe
  • United States
  • Pharmaceutical
  • Infectious Disease
  • Company research
  • Company
  • Drug Approval

Crohn’s Disease: Marketed Drugs

  • $ 7393
  • December 2017
  • 89 pages

Description In-depth analysis of key marketed drugs for Crohn’s disease across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Includes clinical data and provides ...

  • Spain
  • France
  • Monoclonal Antibody
  • Biopharmaceutical
  • Industry analysis
  • Biosimilar Penetration Rate

Abilify/Abilify Maintena

  • $ 10000
  • April 2018
  • 61 pages

Drug Overview  Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist ...

  • United States
  • European Union
  • Antipsychotic
  • Cardiovascular Drug
  • Industry analysis

Seroquel/Seroquel XR

  • $ 10000
  • April 2018
  • 46 pages

Drug Overview  The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, ...

  • Europe
  • Japan
  • Bipolar Disorder
  • Industry analysis

Drug Overview: Lamictal and Lamictal XR

  • $ 10000
  • April 2018
  • 38 pages

Drug Overview  Lamictal (GlaxoSmithKline) contains lamotrigine, a phenyltriazine antiepileptic drug that acts at voltage-sensitive sodium channels to stabilize neuronal membranes and inhibits the ...

  • United States
  • European Union
  • Bipolar Disorder
  • Antipsychotic
  • Industry analysis

Drug Overview: Latuda

  • $ 10000
  • April 2018
  • 33 pages

Drug Overview  Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. ...

  • Europe
  • European Union
  • Antipsychotic
  • Cardiovascular Drug
  • Industry analysis

Drug Overview: Risperdal Consta

  • $ 10000
  • April 2018
  • 26 pages

Drug Overview  Risperdal Consta (Johnson&Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine ...

  • United States
  • European Union
  • Bipolar Disorder
  • Antipsychotic
  • Industry analysis

Drug Overview: Geodon

  • $ 10000
  • April 2018
  • 20 pages

Drug Overview  Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer. Geodon initially launched in the US in 2001 for the treatment of schizophrenia. ...

  • Japan
  • United States
  • Bipolar Disorder
  • Psychotic Disorder
  • Industry analysis

Drug Overview: Xarelto

  • $ 10000
  • March 2018
  • 56 pages

Drug Overview Xarelto (rivaroxaban; Bayer/Johnson&Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan. It inhibits ...

  • Japan
  • United States
  • Cardiovascular Disease
  • Industry analysis

Drug Analysis: Nucala

  • $ 10000
  • February 2018
  • 26 pages

Drug Overview Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, ...

  • Japan
  • United States
  • Asthma
  • Monoclonal Antibody
  • Industry analysis

Drug Analysis: Symbicort

  • $ 10000
  • February 2018
  • 27 pages

Drug Overview AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting ...

  • Japan
  • United States
  • Pharmaceutical
  • Respiratory Treatment
  • Industry analysis

Drug Analysis: Cinqair

  • $ 10000
  • February 2018
  • 16 pages

Drug Overview Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, ...

  • United States
  • European Union
  • Monoclonal Antibody
  • Asthma
  • Industry analysis

Drug Overview: Nucala

  • $ 10000
  • February 2018
  • 26 pages

Drug Overview Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, ...

  • Japan
  • United States
  • Asthma
  • Monoclonal Antibody
  • Industry analysis

Drug Overview: Symbicort

  • $ 10000
  • February 2018
  • 27 pages

Drug Overview AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting ...

  • Japan
  • United States
  • Pharmaceutical
  • Respiratory Treatment
  • Industry analysis

Drug Overview: Cinqair

  • $ 10000
  • February 2018
  • 16 pages

Drug Overview Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, ...

  • United States
  • European Union
  • Monoclonal Antibody
  • Asthma
  • Industry analysis

Drug Analysis: Finerenone

  • $ 10000
  • February 2018
  • 19 pages

Drug Overview Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of ...

  • Europe
  • Japan
  • Heart Failure
  • Hormone
  • Industry analysis

Drug Overview: Finerenone

  • $ 10000
  • February 2018
  • 19 pages

Drug Overview Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of ...

  • Europe
  • Japan
  • Heart Failure
  • Hormone
  • Industry analysis

Drug Analysis: Feraccru

  • $ 10000
  • January 2018
  • 15 pages

Drug Overview Feraccru (ferric trimaltol; Shield Therapeutics/AOP Orphan Pharmaceuticals) is a novel oral ferric iron form with hematinic activity being investigated for the treatment of anemia in chronic ...

  • Europe
  • Iron Oxide
  • Therapy
  • Industry analysis

Drug Analysis: Mircera

  • $ 10000
  • January 2018
  • 20 pages

Drug Overview Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator. The ...

  • Europe
  • Japan
  • Clinical Trial
  • Biopharmaceutical
  • Industry analysis

Drug Overview: Feraccru

  • $ 10000
  • January 2018
  • 15 pages

Drug Overview Feraccru (ferric trimaltol; Shield Therapeutics/AOP Orphan Pharmaceuticals) is a novel oral ferric iron form with hematinic activity being investigated for the treatment of anemia in chronic ...

  • Europe
  • Iron Oxide
  • Therapy
  • Industry analysis

Drug Overview: Mircera

  • $ 10000
  • January 2018
  • 20 pages

Drug Overview  Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator.  The ...

  • Europe
  • Japan
  • Clinical Trial
  • Biopharmaceutical
  • Industry analysis

Azilect (Copy)

  • $ 9000
  • October 2017
  • 14 pages

Drug Overview Azilect (Teva) is a pure isomer of rasagiline and is the most recent selective irreversible monoamine oxidase inhibitor to enter the market. Azilect prolongs the activity of dopamine in ...

  • World
  • United States
  • Generic Drug
  • Psychotic Disorder
  • Industry analysis

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on